Literature DB >> 12495797

Behavioral naltrexone therapy: an integrated treatment for opiate dependence.

Jami L Rothenberg1, Maria A Sullivan, Sarah H Church, Angela Seracini, Eric Collins, Herbert D Kleber, Edward V Nunes.   

Abstract

Treatment of opiate dependence with naltrexone has been limited by poor compliance. Behavioral Naltrexone Therapy (BNT) was developed to promote adherence to naltrexone and lifestyle changes supportive of abstinence, by incorporating components from empirically validated treatments, including Network Therapy with a significant other to monitor medication compliance, the Community Reinforcement Approach, and voucher incentives. An overview is presented of the BNT treatment manual. In an uncontrolled Stage I trial (N = 47), 19% completed the 6-month course of treatment. Retention was especially poor in the subsample of patients who were using methadone at baseline (N = 18; 39% completed 1 month, none completed 6 months), and more encouraging among heroin-dependent patients (N = 29; 65% completed 1 month, 31% completed 6 months). Thus, attrition continues to be a serious problem for naltrexone maintenance, although further efforts to develop interventions such as BNT are warranted.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12495797     DOI: 10.1016/s0740-5472(02)00301-x

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  36 in total

1.  Novel 3-O-pegylated carboxylate and 3-O-pegylated carbamate prodrugs of naltrexone for microneedle-enhanced transdermal delivery.

Authors:  Thirupathi Reddy Yerramreddy; Mikolaj Milewski; Narsimha Reddy Penthala; Audra L Stinchcomb; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2010-04-18       Impact factor: 2.823

Review 2.  Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.

Authors:  Stacey C Sigmon; Adam Bisaga; Edward V Nunes; Patrick G O'Connor; Thomas Kosten; George Woody
Journal:  Am J Drug Alcohol Abuse       Date:  2012-03-12       Impact factor: 3.829

3.  Advances in opioid antagonist treatment for opioid addiction.

Authors:  Walter Ling; Larissa Mooney; Li-Tzy Wu
Journal:  Psychiatr Clin North Am       Date:  2012-04-10

Review 4.  Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available.

Authors:  Evgeny Krupitsky; Edwin Zvartau; George Woody
Journal:  Curr Psychiatry Rep       Date:  2010-10       Impact factor: 5.285

5.  Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin.

Authors:  Maria A Sullivan; Suzanne K Vosburg; Sandra D Comer
Journal:  Psychopharmacology (Berl)       Date:  2006-09-14       Impact factor: 4.530

Review 6.  Oral naltrexone maintenance treatment for opioid dependence.

Authors:  Silvia Minozzi; Laura Amato; Simona Vecchi; Marina Davoli; Ursula Kirchmayer; Annette Verster
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

Review 7.  Behavioral counseling content for optimizing the use of buprenorphine for treatment of opioid dependence in community-based settings: a review of the empirical evidence.

Authors:  Michael M Copenhaver; R Douglas Bruce; Frederick L Altice
Journal:  Am J Drug Alcohol Abuse       Date:  2007       Impact factor: 3.829

8.  Betting on change: modeling transitional probabilities to guide therapy development for opioid dependence.

Authors:  Kenneth M Carpenter; Huiping Jiang; Maria A Sullivan; Adam Bisaga; Sandra D Comer; Wilfrid Noel Raby; Adam C Brooks; Edward V Nunes
Journal:  Psychol Addict Behav       Date:  2009-03

9.  Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence.

Authors:  Wilfrid Noel Raby; Kenneth M Carpenter; Jami Rothenberg; Adam C Brooks; Huiping Jiang; Maria Sullivan; Adam Bisaga; Sandra Comer; Edward V Nunes
Journal:  Am J Addict       Date:  2009 Jul-Aug

10.  Physicochemical evaluation, in vitro human skin diffusion, and concurrent biotransformation of 3-O-alkyl carbonate prodrugs of naltrexone.

Authors:  Omathanu Pillai; Mohamed O Hamad; Peter A Crooks; Audra L Stinchcomb
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.